Litigation Details for BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2016)

« Back to Dashboard

BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2016)

Docket	1:16-cv-00175	Date Filed	2016-03-18
Court	District Court, D. Delaware	Date Terminated	2017-10-13
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,579,019; 8,147,866; 8,703,177; 9,522,188
Link to Docket	External link to docket

Details for BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-18				External link to document
2016-03-18	100		Disclosures of Plaintiffs with Regard to U.S. Patent No. 9,522,188 filed by Arius Two, Inc., BioDelivery Sciences…2016 13 October 2017 1:16-cv-00175 830 Patent None District Court, D. Delaware	External link to document
2016-03-18	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,579,019 B2; 8,147,866 B2; 8,703,177…2016 13 October 2017 1:16-cv-00175 830 Patent None District Court, D. Delaware	External link to document

BioDelivery Sciences International v. Actavis Laboratories UT: Belbuca Patent Litigation Summary and Analysis, 1:16-cv-00175

Last updated: August 26, 2026

BioDelivery Sciences International, Inc. sued Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware after Actavis filed an abbreviated new drug application seeking approval for a generic version of BELBUCA, an extended-release buprenorphine buccal film. The case, No. 1:16-cv-00175-RGA, was an ANDA patent action under the Hatch-Waxman Act.

The dispute involved patents covering BELBUCA’s buccal-film composition, drug-delivery properties, and methods of use. The case ended through settlement and dismissal rather than a final merits decision on patent validity or infringement. The settlement delayed Actavis’s generic entry until the agreed launch date and preserved BDSI’s commercial exclusivity for the principal patent term.

What was BioDelivery Sciences v. Actavis Laboratories about?

The litigation concerned Actavis’s ANDA for a generic buprenorphine buccal film equivalent to BELBUCA. BDSI alleged that the ANDA filing itself infringed BELBUCA patents under 35 U.S.C. § 271(e)(2).

Item	Details
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-00175-RGA
Plaintiff	BioDelivery Sciences International, Inc.
Defendant	Actavis Laboratories UT, Inc., an Actavis/Teva generic subsidiary
Brand	BELBUCA
Active ingredient	Buprenorphine
Dosage form	Extended-release buccal film
Regulatory pathway	ANDA
ANDA number	208411
Filing date	2016
Legal basis	Hatch-Waxman patent infringement
Resolution	Settlement and dismissal
Trial outcome	No final trial judgment on validity or infringement

BDSI’s complaint followed Actavis’s Paragraph IV certification against patents listed for BELBUCA in the FDA’s Orange Book. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Which patents did BDSI assert against Actavis?

BDSI asserted a group of patents relating to BELBUCA’s bioadhesive film technology. The patents identified in the litigation included U.S. Patent Nos. 8,147,866, 8,173,718, 8,546,437, and 8,778,394.

Patent	General subject matter	Role in the case
U.S. 8,147,866	Bioadhesive drug-delivery compositions and related use claims	Asserted against Actavis
U.S. 8,173,718	Buccal-film composition and delivery technology	Asserted against Actavis
U.S. 8,546,437	Bioadhesive film and pharmaceutical delivery claims	Asserted against Actavis
U.S. 8,778,394	Related buccal-film formulation and use claims	Asserted against Actavis

The patents arose from a common technology platform involving drug delivery through the buccal mucosa. The claims were directed to more than the presence of buprenorphine. They addressed the film matrix, adhesion, release profile, dosage administration, and therapeutic use.

Later Orange Book listings for BELBUCA included additional continuation or related patents. Those later patents should not be treated as adjudicated in the 2016 Actavis case unless they were separately asserted or incorporated into the litigation record.

What was the Orange Book status of BELBUCA?

The FDA listed BELBUCA-related patents in the Orange Book, and BDSI relied on those listings to initiate the patent case after receiving Actavis’s Paragraph IV notice.

BELBUCA is an NDA product approved under NDA 207932. The Orange Book patent listings provide the regulatory basis for a generic applicant’s patent certifications and for a brand company’s Hatch-Waxman litigation.

The listing strategy had two commercial effects:

1. It required Actavis to address the listed patents in its ANDA certification.
2. It triggered the statutory 30-month stay of FDA approval upon BDSI’s timely infringement action, subject to court orders and statutory exceptions.

The litigation therefore delayed FDA approval even before the court determined whether the patents were valid or infringed.

What did Actavis challenge in its Paragraph IV filing?

Actavis challenged BDSI’s patent rights through Paragraph IV certifications. The certification position put the asserted patents directly at issue and allowed BDSI to sue under the Hatch-Waxman framework.

The public case record identifies the core dispute as an ANDA patent challenge involving Actavis’s proposed generic buprenorphine buccal film. The case did not produce a published merits opinion holding that the asserted patents were invalid, unenforceable, or not infringed.

The practical significance of the Paragraph IV filing was commercial rather than merely procedural. Actavis sought a regulatory path to market a competing film product before the nominal end of the asserted patent estate. BDSI used the litigation to negotiate a controlled launch date.

When does the BELBUCA patent estate lose exclusivity?

The principal patents asserted in the case had nominal expiration in 2027, subject to patent-term adjustment, patent-term extension, and the specific expiration date recorded for each patent in the FDA and USPTO databases.

Exclusivity component	Approximate timing or status
Core asserted patents	Generally expiring in 2027
FDA new chemical entity exclusivity	Not the principal barrier in the Actavis case
30-month stay	Triggered by the timely ANDA litigation
Actavis generic launch	Controlled by the settlement agreement
Post-settlement competition	Dependent on the agreed launch provision and other valid patents

BELBUCA’s commercial protection was driven primarily by patents, not by biologic exclusivity or a long-term regulatory exclusivity period. Buprenorphine is an established active ingredient, so the relevant protection focused on the branded delivery system and its approved use.

The settlement allowed Actavis to enter before or at the end of the full patent term under agreed conditions. A settlement launch date is not the same as patent expiration. It is a contractual license date that can be earlier than expiration.

How was the litigation resolved?

BDSI and Actavis resolved the dispute through a confidential settlement agreement followed by dismissal. The court did not issue a final judgment on the asserted patents.

The settlement structure is consistent with the standard ANDA resolution model:

• BDSI granted Actavis a license to market a generic BELBUCA product on an agreed date.
• Actavis agreed not to launch before that date.
• The parties dismissed the infringement claims.
• The court’s dismissal eliminated the need for trial and post-trial patent rulings.
• The agreement reduced the risk of an immediate generic launch while giving Actavis a defined future entry path.

Public company disclosures described the resolution as permitting a future Actavis launch under the settlement terms. The agreement did not establish that the asserted patents were valid or infringed. It also did not create a judicial finding that Actavis’s product would have infringed the patents.

Was there a final ruling on patent validity or infringement?

No. The case ended without a merits adjudication.

There was no final district court judgment determining:

• Whether the asserted claims were valid;
• Whether the claims were enforceable;
• Whether Actavis’s proposed product infringed;
• Whether the claims covered all possible generic buprenorphine films; or
• Whether the Orange Book listings were improper.

This distinction matters for patent-strength analysis. A settlement can preserve revenue and delay competition, but it does not provide the evidentiary value of a favorable claim-construction ruling, summary judgment, bench trial, or jury verdict.

What formulation patents protected BELBUCA?

The BELBUCA patents protected the delivery platform rather than merely the active ingredient. The relevant technical areas included:

Buccal adhesion

The film was designed to adhere to the inside of the cheek and deliver buprenorphine over an extended period. Adhesion claims can create a barrier against substitution if the generic product must reproduce a comparable mucosal-delivery mechanism.

Film composition

The asserted claims addressed combinations of polymers, drug content, and other film components. Formulation claims can be difficult to design around when the approved product’s performance depends on a narrow balance of adhesion, dissolution, flexibility, and drug release.

Controlled release

BELBUCA delivers buprenorphine through a sustained buccal system. Claims directed to release characteristics or administration methods can create separate infringement theories from composition claims.

Method of use

The patent estate included claims relating to administering buprenorphine through the buccal film. Method-of-use claims may be important where the generic label includes the patented indication or dosing instructions.

The existence of these claim categories does not establish that every generic film would infringe. The scope depends on the asserted claim language, prosecution history, ANDA product description, and the court’s interpretation of the claims.

How strong was BDSI’s patent position in the Actavis case?

BDSI’s litigation position was commercially effective but legally untested at final judgment.

Strength factor	Assessment
Orange Book listing	Supported a statutory Hatch-Waxman action
Multiple patents	Increased the number of claims and potential entry barriers
Formulation coverage	Addressed product architecture rather than only the ingredient
Method-of-use coverage	Added label-based infringement theories
Settlement result	Delayed immediate Actavis competition
Merits ruling	None
Invalidity risk	Not resolved by the court
Design-around risk	Depended on the scope of the claims and Actavis’s formulation

The strongest practical point was portfolio layering. BDSI asserted multiple patents covering related aspects of the same delivery system. A generic applicant had to address the collective risk of infringement, discovery expense, an FDA approval stay, and possible damages or injunctive relief.

The principal weakness was the absence of a merits decision. Investors and licensing counterparties cannot cite the case as proof that the patents would have survived validity challenges or that the proposed Actavis product infringed.

What was the commercial impact of the Actavis settlement?

The settlement protected BELBUCA from an immediate Actavis launch and converted an uncertain litigation outcome into a defined competitive timetable.

For BDSI, the settlement offered:

• Continued control of the BELBUCA market during the agreed pre-entry period;
• Reduced litigation cost and trial risk;
• Greater predictability for revenue forecasting;
• Protection against an adverse invalidity or noninfringement judgment.

For Actavis, the settlement offered:

• A defined market-entry date;
• Avoidance of prolonged district court litigation;
• Elimination of the risk of an injunction blocking approval;
• A path to launch without requiring a final victory on every asserted patent.

The agreement did not eliminate competition from other generic applicants. Other ANDA filers could challenge different patents, reach separate settlements, or pursue different launch positions.

Did the case involve biosimilar risk?

No. The case did not involve a biologic or biosimilar application.

BELBUCA is a small-molecule drug product delivered through a buccal film. The relevant regulatory pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.

The competitive risks were:

• Generic buprenorphine buccal film entry;
• Paragraph IV patent challenges;
• Formulation design-arounds;
• Separate ANDA filings;
• Contractual launches under patent settlements.

Biosimilar interchangeability, reference-product exclusivity, and biologic patent dance procedures were not relevant to this action.

What litigation and settlement risks remained after dismissal?

Dismissal ended the specific Actavis case but did not terminate the broader BELBUCA patent program.

Later patent challenges

A later ANDA applicant could challenge patents issued or listed after the original complaint. A settlement with one applicant does not bind unrelated generic companies unless they separately agree to similar terms.

Formulation differences

Actavis’s proposed product could differ from BELBUCA in polymers, drug loading, film dimensions, release characteristics, or manufacturing processes. Those differences can affect both infringement risk and the scope of any future litigation.

Manufacturing and process barriers

Manufacturing know-how may provide commercial protection even when a formulation patent is vulnerable. Scale-up of a mucoadhesive film requires control of uniformity, adhesion, dissolution, drug distribution, and packaging stability. These factors are not substitutes for patent rights, but they can affect the speed and quality of generic entry.

Regulatory label strategy

Method-of-use patents can be challenged through label carve-outs or other regulatory strategies. The viability of a carve-out depends on the patented indication, the proposed generic label, and whether the remaining labeled uses still create infringement exposure.

How does the Actavis case compare with a contested ANDA trial?

Issue	Actavis settlement	Contested ANDA trial
Patent validity	Unresolved	Decided by court
Infringement	Unresolved	Decided on the ANDA product
Entry timing	Contractually fixed	Determined by judgment, injunction, and approval status
Litigation cost	Reduced after settlement	Typically higher
Precedential value	Limited	Potentially significant
Revenue forecast	More predictable	Dependent on litigation outcome
Patent-strength evidence	Commercial only	Legal and evidentiary record

For BDSI, the settlement was favorable in timing terms but neutral on the underlying legal merits. It protected near-term sales without validating the patent estate through a final opinion.

What is the current legal significance of 1:16-cv-00175?

The case is best characterized as a resolved Hatch-Waxman patent dispute involving BELBUCA’s buccal-film technology. It is not a precedent establishing the validity or infringement scope of the asserted patents.

The main legal conclusions are:

1. Actavis’s ANDA filing created an actionable patent dispute.
2. BDSI asserted multiple formulation and use patents.
3. The parties settled before a final merits ruling.
4. The settlement established a controlled generic-entry framework.
5. The case did not resolve the broader validity of BDSI’s patent estate.
6. Subsequent generic entrants remained capable of creating separate litigation risk.

Key Takeaways

• BioDelivery Sciences sued Actavis Laboratories UT in Delaware over an ANDA for generic BELBUCA.
• The case involved buprenorphine buccal-film patents, including U.S. Patent Nos. 8,147,866, 8,173,718, 8,546,437, and 8,778,394.
• Actavis used Paragraph IV certifications to challenge the Orange Book-listed patents.
• The litigation was resolved by settlement and dismissal, not by a trial or final validity ruling.
• The asserted patent group generally carried 2027 nominal expiration timing.
• The settlement delayed Actavis’s generic entry under a contractual license.
• The case reduced immediate generic-launch risk but did not establish that BDSI’s patents were legally valid or infringed.
• Biosimilar law was not relevant because BELBUCA is a small-molecule drug regulated through the ANDA pathway.
• Later patents, separate ANDA filers, formulation design-arounds, and label strategies remained potential sources of competition.

FAQs About BioDelivery Sciences v. Actavis Laboratories

What drug was at issue in BioDelivery Sciences v. Actavis?

The dispute involved BELBUCA, an extended-release buprenorphine buccal film marketed by BioDelivery Sciences International.

What was Actavis ANDA No. 208411?

ANDA No. 208411 was Actavis’s abbreviated new drug application for a generic version of BELBUCA. BDSI sued after Actavis made Paragraph IV patent certifications.

Did Actavis win the BELBUCA patent case?

Neither party obtained a final merits victory. The case ended through settlement and dismissal before the court ruled on patent validity or infringement.

Could another generic company enter BELBUCA before Actavis?

Yes. The Actavis settlement controlled Actavis’s entry, not necessarily the conduct of unrelated ANDA applicants. Other companies could pursue separate patent challenges and settlements.

Are BELBUCA’s patents composition patents or method-of-use patents?

The BELBUCA estate included formulation and drug-delivery claims, as well as claims relating to administration and therapeutic use. The precise scope depends on each patent’s issued claims and the patent listings applicable at the time.

References

1. BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc., No. 1:16-cv-00175-RGA, Complaint (D. Del. filed Mar. 3, 2016).

2. BioDelivery Sciences International, Inc. v. Actavis Laboratories UT, Inc., No. 1:16-cv-00175-RGA, docket record (D. Del.).

3. BioDelivery Sciences International, Inc. U.S. Securities and Exchange Commission filings, including annual reports and current reports addressing BELBUCA intellectual property and Actavis litigation.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book.

5. U.S. Patent and Trademark Office. Patent Center and Patent Assignment Search records for U.S. Patent Nos. 8,147,866, 8,173,718, 8,546,437, and 8,778,394.